Mindstrong Health is a startup company which aims to use smartphones to detect neurological disorders. The company recently announced that it had raised $14 million in an effort to support its neuropsychiatric diagnosis and treatment platform. Mindstrong’s artificial intelligence platform is created to monitor how the use of smart phone affects brain function. The company intends to determine the digital biomarkers of cognition and mood which include memory, attention, processing speed, and executive function. Mindstrong’s AI platform utilizes a patient’s patterns of typing and scrolling on a smartphone to make measurements of their brain function.
The Staff at Mindstrong Health
Mindstrong Health’s staff has a great understanding of the challenges facing the medical community when it comes to caring for patients with mental health disorders. According to Jim Tananbaum, the CEO of Foresite Capital, the collective experience, technical vision, and leadership of Paul, Tom, and Rick, and other parties interested in revolutionizing neuropsychiatric treatment, is enough to improve patient outcomes using a modern and innovative health care platform.
Mindstrong Health’s CEO, Dr. Paul Dagum, recently revealed in a press release that the technology of his company provides continuous and objective measures of a person’s behavior and cognition in a way that has never been seen before. While all modern medicine employs some form of objective measurement, determining mental health is restricted to subjective reports. To improve the outcomes for patients suffering from mental disorders, it is necessary to come up with objective measures like those used for chronic diseases like heart disease and diabetes.
About Jim Tananbaum
Jim Tananbaum is the founder and CEO of Foresite Capital, a firm that manages $1.1 billion worth of assets. Jim has over 20 years’ worth of experience in building and investing in health care institutions. According to medium.com, before establishing Foresite Capital, Tananbaum co-founded two healthcare investment firms and two biopharmaceutical firms.
After completing Harvard Medical School, Jim established “GelTex Pharmaceuticals” which introduced two drugs to the healthcare market for under $80 million, currently; these drugs generate revenues of up to $1 billion. GelTex was later purchased for $1.6 billion. Jim is also the founder of “Theravance Inc” and “Theravance Biopharma”, which combined have a market value of $2.75 billion.